Frequency and timing of loss of imprinting at 11p13 and 11p15 in Wilms' tumor development
- PMID: 18644976
- DOI: 10.1158/1541-7786.MCR-08-0002
Frequency and timing of loss of imprinting at 11p13 and 11p15 in Wilms' tumor development
Abstract
Epigenetic changes occur frequently in Wilms' tumor (WT), especially loss of imprinting (LOI) of IGF2/H19 at 11p15. Our previous results have identified imprinted transcripts (WT1-AS and AWT1) from the WT1 locus at 11p13 and showed LOI of these in some WTs. In this article, we set out to test the relationship between LOI at 11p13 and 11p15 and their timing in WT progression relative to other genetic changes. We found a higher level (83%) of 11p13 LOI in WT than of 11p15 LOI (71%). There was no correlation between methylation levels at the 11p13 and 11p15 differentially methylated regions or between allelic expression of WT1-AS/AWT1 and IGF2. Interestingly, retention of normal imprinting at 11p13 was associated with a small group of relatively late-onset, high-stage WTs. An examination of genetic and epigenetic alterations in nephrogenic rests, which are premalignant WT precursors, showed that LOI at both 11p13 and 11p15 occurred before either 16q loss of heterozygosity (LOH) or 7p LOH. This suggests that these LOH events are very unlikely to be a cause of LOI but that LOH may act by potentiating the effects of overexpression of IGF2 and/or WT1-AS/AWT1 that result from LOI.
Similar articles
-
Genomic profiling maps loss of heterozygosity and defines the timing and stage dependence of epigenetic and genetic events in Wilms' tumors.Mol Cancer Res. 2005 Sep;3(9):493-502. doi: 10.1158/1541-7786.MCR-05-0082. Mol Cancer Res. 2005. PMID: 16179496
-
Association of 11q loss, trisomy 12, and possible 16q loss with loss of imprinting of insulin-like growth factor-II in Wilms tumor.Genes Chromosomes Cancer. 2006 Jun;45(6):592-601. doi: 10.1002/gcc.20321. Genes Chromosomes Cancer. 2006. PMID: 16518847
-
Frequent loss of imprinting of the H19 gene is often associated with its overexpression in human lung cancers.Oncogene. 1995 Mar 16;10(6):1193-8. Oncogene. 1995. PMID: 7700644
-
[Altered genomic imprinting in the IGF2 and H19 genes in human lung cancer].Nihon Rinsho. 1996 Feb;54(2):492-6. Nihon Rinsho. 1996. PMID: 8838103 Review. Japanese.
-
Epigenetic deregulation of imprinting in congenital diseases of aberrant growth.Bioessays. 2006 May;28(5):453-9. doi: 10.1002/bies.20407. Bioessays. 2006. PMID: 16615080 Review.
Cited by
-
The epithelial splicing regulator ESRP2 is epigenetically repressed by DNA hypermethylation in Wilms tumour and acts as a tumour suppressor.Mol Oncol. 2022 Feb;16(3):630-647. doi: 10.1002/1878-0261.13101. Epub 2021 Sep 28. Mol Oncol. 2022. PMID: 34520622 Free PMC article.
-
The prevalence of loss of imprinting of H19 and IGF2 at birth.FASEB J. 2013 Aug;27(8):3335-43. doi: 10.1096/fj.12-225284. Epub 2013 Apr 25. FASEB J. 2013. PMID: 23620526 Free PMC article.
-
ALKBH5 gene polymorphisms and Wilms tumor risk in Chinese children: A five-center case-control study.J Clin Lab Anal. 2020 Jun;34(6):e23251. doi: 10.1002/jcla.23251. Epub 2020 Feb 24. J Clin Lab Anal. 2020. PMID: 32091154 Free PMC article.
-
Imprinted genes in myeloid lineage commitment in normal and malignant hematopoiesis.Leukemia. 2015 Jun;29(6):1233-42. doi: 10.1038/leu.2015.47. Epub 2015 Feb 23. Leukemia. 2015. PMID: 25703588 Review.
-
Frequent long-range epigenetic silencing of protocadherin gene clusters on chromosome 5q31 in Wilms' tumor.PLoS Genet. 2009 Nov;5(11):e1000745. doi: 10.1371/journal.pgen.1000745. Epub 2009 Nov 26. PLoS Genet. 2009. PMID: 19956686 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous